Day: March 29, 2022

Delivers strong profitability and over $1 billion in free cash flow BOISE, Idaho, March 29, 2022 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) today announced results for its second quarter of fiscal 2022, which ended March 3, 2022. Fiscal Q2 2022 highlightsRevenue of $7.79 billion versus $7.69 billion for the prior quarter and $6.24 billion for the same period last year GAAP net income of $2.26 billion, or $2.00 per diluted share Non-GAAP net income of $2.44 billion, or $2.14 per diluted share Operating cash flow of $3.63 billion versus $3.94 billion for the prior quarter and $3.06 billion for the same period last year“Micron’s excellent second quarter results exceeded the high end of our guidance for both revenue and margin, reflecting our strong execution,” said Micron Technology President and CEO Sanjay Mehrotra....

Received FDA clearance in February 2022 to market Pure-Vu EVS, an all new, next-generation system that has been deployed to multiple hospitals in the first few weeks since launchDoubled the size of the sales team since November, and plan to continue investing in commercial expansion throughout 2022Advancing strategy to secure reimbursement for the Pure-Vu System for certain outpatient colonoscopies, targeting ~4.7M outpatient procedures per year in the U.S.FORT LAUDERDALE, Fla., March 29, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its...

Total revenue for 2021 was approximately $4.3 million Strong total cash position of approximately $36.1 million as of December 31, 2021, up significantly from $13.4 million at year-end 2020 Conference call to be held March 29, 2022 at 4:30 p.m. EDTROCKVILLE, Md., March 29, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2021 and full-year 2021 financial and operating results and provided a business update. OpGen’s revenue for the fourth quarter of 2021 was approximately $1.43 million, a 5% increase from $1.35 million in Q4 2020. Its total revenue for 2021 was approximately $4.3 million, up 2% from $4.2 million in 2020. “We are pleased...

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. “2022 is on track to be an important year for Adverum, as we progress our plan to initiate a Phase 2 trial evaluating two doses of ADVM-022 in patients with wet age-related macular degeneration,” stated Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. “Given our robust safety review of all 55 patients treated with ADVM-022, promising clinical efficacy data generated in our OPTIC study in wet age-related macular degeneration and cash runway into 2024, we are able to approach...

Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipeline Clinical development commencing for two programs that incorporate Lyell’s novel reprogramming technologiesSOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported fourth quarter and full year 2021 financial results and provided business highlights. “With the recent FDA clearance of two INDs that incorporate our novel genetic and epigenetic reprogramming technologies, we are now a clinical stage-company advancing a pipeline of novel cell therapies for patients with solid tumors,” said Liz Homans, CEO of Lyell Immunopharma....

CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today reported financial results for the full year ended December 31, 2021 and provided a business update. “2021 was a transformational year for Pardes, culminating in the completion of our business combination and successful financing, which positioned us well to continue working urgently to develop PBI-0451 as a potential stand-alone oral antiviral drug candidate for the treatment and prevention of COVID-19. We have seen oral antiviral treatments begin to emerge, and while they are a great starting...

SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission. The Company will also hold an update conference call at 4:30 PM ET in which it will discuss business highlights. Following management’s formal remarks, there will be a question and answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10164538/f1ee9a93ce.  Please note that registered participants will receive their dial-in number upon registration.  For those who have not registered, to listen...

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives. Business UpdateTricida continued to execute on the conduct of the VALOR-CKD renal outcomes clinical trial. Enrollment of patients in the VALOR-CKD trial was completed at the end of 2021 with 1,480 subjects randomized. As of March 28, 2022, randomized subjects had an average treatment duration of approximately 24 months, and the trial had accrued 217 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease (ESRD), or greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR).  Upcoming MilestoneTricida...

– Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis – – Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – – Strengthened Board with the appointments of Lyn Baranowski and Lisa Rometty – – Conference call and webcast today at 4:30 p.m. ET – SAN JOSE, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “The year 2021 and the subsequent months that have passed have been a productive period for Rani. We refined and progressed our development...

Ended 2021 with $217 million in unrestricted cash and cash equivalents Completed assembly and began initial testing of the initial Guardian® XT™ “Beta” unit Completed scheduled move into new headquarters in Salt Lake City SALT LAKE CITY, March 29, 2022 (GLOBE NEWSWIRE) — Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC and STRCW), a leader in the development of highly dexterous robotic systems that augment humans to enhance productivity and safety, today announced financial results for the quarter and full-year ended December 31, 2021. Recent highlights include:Announced the planned acquisition of RE2 Robotics, an award-winning developer of intelligent mobile manipulation systems Started testing of the Guardian® XO® Beta unit functionality Appointed Kiva Allgood as new President and Chief Executive Officer Completed...